small cell carcinoma, sarcomatoid urothelial carcinoma, micropapillary carcinoma, plasmacytoid carcinoma, adenocarcinoma, and urachal carcinoma. The role of neoadjuvant and adjuvant chemotherapy ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.